Christine Placet – CEO, Horama, France

Christine Placet, CEO of French biotech Horama, discusses the objective of becoming one of the key players in the field of ophthalmic gene therapy. She explains how Horama’s unique pipeline can be a solution to unmet medical needs in retinal dystrophy and goes on to share her personal insights on the biotech environment of France.  
Many [biotech] companies are obliged to leave France or be bought out by Big Pharma, making it impossible to create the next big French success story
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report